𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Neuropsychological performance, disease severity, and depression in progressive supranuclear palsy

✍ Scribed by Thomas Esmonde; Elaine Giles; Mark Gibson; John R. Hodges

Book ID
104988619
Publisher
Springer
Year
1996
Tongue
English
Weight
675 KB
Volume
243
Category
Article
ISSN
0340-5354

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Gray matter correlates of behavioral sev
Gray matter correlates of behavioral severity in progressive supranuclear palsy
✍ Keith A. Josephs; Jennifer L. Whitwell; Scott D. Eggers; Matthew L. Senjem; Clif πŸ“‚ Article πŸ“… 2011 πŸ› John Wiley and Sons 🌐 English βš– 293 KB

## Background: Behavioral changes occur in progressive supranuclear palsy. this study aimed to identify the anatomic correlate of behavioral severity in progressive supranuclear palsy. ## Methods: We performed standardized tests of behavioral severity (frontal behavioral inventory), cognitive sev

Staging disease severity in movement dis
Staging disease severity in movement disorder tauopathies: Brain atrophy separates progressive supranuclear palsy from corticobasal degeneration
✍ Emma C. Schofield; Diana Caine; Jillian J. Kril; Nicholas J. Cordato; Glenda M. πŸ“‚ Article πŸ“… 2004 πŸ› John Wiley and Sons 🌐 English βš– 166 KB

## Abstract The movement disorders progressive supranuclear palsy (PSP) and corticobasal degeneration (CBD) both deposit tau in degenerating neurons and are considered to be tauopathies. The recently developed scheme for staging tissue degeneration in another tauopathy, frontotemporal dementia [Bro

Brain iron deposition fingerprints in Pa
Brain iron deposition fingerprints in Parkinson's disease and progressive supranuclear palsy
✍ Kai Boelmans; Brigitte Holst; Marc Hackius; JΓΌrgen Finsterbusch; Christian Gerlo πŸ“‚ Article πŸ“… 2012 πŸ› John Wiley and Sons 🌐 English βš– 944 KB

## Abstract It can be difficult to clinically distinguish between classical Parkinson's disease (PD) and progressive supranuclear palsy. Previously, there have been no biomarkers that reliably allow this distinction to be made. We report that an abnormal brain iron accumulation is a marker for ongo